Recent Updates

340B Newsletter, November 16, 2026: Pilot Hearing, New CMS Rules and the Midterms

Two weeks of 340B news: the rebate pilot court hearing, three CMS rules for 2027 and beyond, Congress after the midterms, new manufacturer restrictions and state contract pharmacy cases.

NewsletterCovered entities & pharmaciesNovember 16, 20267 min readBy the Secure340B team

Covers November 2 to 16, 2026.

The 2027 rebate pilot faces its key court test this week, when a federal judge in Maine hears arguments on November 18 on whether to block it before its January 1 start. Democrats will control both chambers of Congress from January 3, but stopping the pilot before then looks unlikely. CMS finalized three rules that take effect in 2027 or later. Two more drugmakers announced contract pharmacy restrictions, and state contract pharmacy laws stayed in court in four states.

1. The 2027 rebate pilot

  • Hearing set for November 18. In AHA v. Kennedy (D. Me., No. 1:26-cv-00515), Chief Judge Lance Walker set oral argument for 9 a.m. on November 18 in Portland on the hospitals' request to temporarily block the pilot. He blocked HRSA's first pilot in December 2025. HHS, the drugmaker intervenors and PhRMA filed their oppositions on November 3.
  • Congress unlikely to act before January 1. Rep. Raul Ruiz (D-Calif.) said on November 10 that blocking the pilot in the lame-duck session would be "very difficult." None of the pending bills (H.R. 10770, the PROTECT 340B Act and H.R. 10919) has moved.
  • The cash cost, in one example. A study for Russell County Hospital, a 25-bed critical access hospital in Kentucky, projects its upfront spending on pilot drugs will rise 153%, from about $346,000 to about $875,000. Eliquis, Jardiance, Januvia, Vraylar and Tradjenta drive most of the increase.
  • Scope unchanged. The pilot still covers 10 manufacturers, all planning to use Beacon.

2. CMS rules for 2027 and beyond

  • Part B cut for 340B hospitals (November 4). From January 1, 2027, Medicare pays ASP minus 28% for separately payable Part B drugs bought at 340B prices, down from ASP plus 6%. Drugs bought outside 340B stay at ASP plus 6%. Rural sole community, children's and PPS-exempt cancer hospitals are exempt. Every separately payable drug line needs a JG, TB or ND modifier. CMS says hospitals may buy outside 340B if they follow all required guidance and regulations.
  • Part D 340B claims reporting (November 4). Covered entities must report Part D 340B claims for dates of service from January 1, 2027. The first file, covering January through June, is due September 30, 2027.
  • Drug price negotiation final rule (November 5). It takes effect December 5 and covers drugs negotiated for 2029 and later. CMS will address how the Medicare negotiated price (MFP) reaches pharmacies in separate guidance.
  • HRSA to CMS. No transfer of the 340B program to CMS has been formally announced.

3. Congress after the midterms

Democrats will control the House and Senate when the new Congress convenes January 3. Rep. Doris Matsui (D-Calif.), a lead sponsor of the PROTECT 340B Act, won reelection and could lead the House Energy and Commerce health subcommittee. Sen. Bernie Sanders is expected to chair the Senate HELP Committee, with Sen. Rand Paul as its top Republican. Several 340B critics will not return, including HELP Chair Bill Cassidy, who lost his primary earlier this year. Sen. John Thune, part of the bipartisan group behind the SUSTAIN Act, remains Senate Republican leader.

4. Manufacturer restrictions and data requirements

  • Medexus became the 46th manufacturer with contract pharmacy restrictions. From January 1, 2027, covered entities may use one contract pharmacy for Rasuvo and must submit claims data within 45 days of dispensing.
  • Fresenius Kabi became the 45th, with new contract pharmacy restrictions and in-house data requirements.
  • GSK and Sobi exempted more states from their claims data requirements: GSK added Louisiana and Arkansas, and Sobi added Louisiana.

5. CVS

CVS Health announced on November 4 that it will split into two public companies. The December 1 deadline for covered entities to sign CVS's new 340B pharmacy services agreement still applies. No rulings have been reported on CVS's motions to dismiss the hospital suits.

6. State contract pharmacy laws

  • Arkansas: 13 drugmakers and Second Sight Solutions, which runs Beacon and 340B ESP, asked a federal court to dismiss the attorney general's suit.
  • Illinois: the state's primary care association moved to join the case on November 6. A ruling on the drugmakers' request to block the law is still pending.
  • Hawaii: the 9th Circuit hears argument on December 1, with a federal government attorney arguing alongside AstraZeneca.
  • Vermont: PhRMA appealed the denial of its injunction to the 2nd Circuit.
  • Maryland and West Virginia: the 4th Circuit's full-court decision is still pending.

7. Other litigation

  • AbbVie v. HRSA (patient definition): fully briefed since September 30; no ruling reported.
  • Orphan drugs: on October 29, a federal judge in Washington, D.C. denied a Michigan hospital's request to retroactively restore its 340B orphan drug pricing, and also denied HRSA's motion to dismiss.

What this means for covered entities

  • Keep preparing for the pilot's January 1 start: finish Beacon registration, banking and users, and check 340B ESP user access for every 340B ID.
  • Decide, drug by drug, whether to buy Medicare Part B drugs on 340B or outside 340B, and set up split billing and the JG, TB and ND modifiers before January 1. Our Medicare Part B article walks through the math.
  • If you use CVS as a contract pharmacy, decide on the new agreement by December 1.
  • Check new manufacturer notices (Medexus, Fresenius Kabi) against your contract pharmacy arrangements and data submissions.
  • Plan for Part D 340B claims reporting for dates of service from January 1, 2027.

What this means for pharmacies

  • No change to how MFP refunds are paid today. Keep reconciling them claim by claim and file a Good Faith Inquiry when one is missing or short.
  • The Medicare Part B cut doesn't apply to retail or contract pharmacy 340B prescriptions.
  • New restrictions (Medexus, Fresenius Kabi) and CVS's December 1 deadline may change which 340B prescriptions your covered entity partners send through you. Check with them now.

Information current as of November 16, 2026. This is general education, not legal or billing advice. 340B Report articles are paraphrased and credited. Sources: Court docket, AHA v. Kennedy; 340B Report, Maine hearing; 340B Report, Nov. 10; Healthcare Finance News; CMS CY 2027 OPPS final rule, Federal Register; Holland & Knight, OPPS final rule; 340B Report, Part D repository; Covington, negotiation rule; 340B Report, webinar recap; 340B Report, Capitol Hill update; 340B Report, Medexus; 340B Report, Fresenius Kabi; 340B Report, GSK and Sobi; 340B Report, CVS split; Frier Levitt, CVS agreements; 340B Report, Arkansas; 340B Report, state litigation; 340B Report, orphan drugs.

Need help applying it?

A clearer path starts
with a conversation.

Talk with our team about your organization and the workflow that needs attention.